‌

US Patent 7527791 Humanized anti-TGF-beta antibodies

Patent 7527791 was granted and assigned to Genentech on May, 2009 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors

Is a

Patent attributes

Current Assignee

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

Date of Patent

May 5, 2009

Patent Application Number

11096046

Date Filed

March 31, 2005

Patent Citations Received

US Patent 12134649 Anti-B7-H4 antibodies and immunoconjugates

0

US Patent 12071475 Antibodies that bind transforming growth factor beta (TGF beta) and methods of use thereof for treatment

0

US Patent 12122842 Human CD30-specific binding proteins and uses thereof

0

US Patent 12129306 Antibodies binding to STEAP-1

0

US Patent 11667716 Bispecific antagonist comprising a LAG-3 binding domain

0

US Patent 11673953 DLL3 targeting chimeric antigen receptors and binding agents

0

US Patent 11673968 Anti-BRDU antibodies and methods of use

0

US Patent 11685790 Antibodies binding to STEAP-1

0

...

Patent Primary Examiner

Patent abstract

Humanized anti-TGF-beta antibodies are provided, as well as methods for their preparation and use, including methods for treating TGF-beta disorders, for example, cancer. Also provided are articles of manufacture designed for various uses that contain the humanized antibodies.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 7527791 Humanized anti-TGF-beta antibodies

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool

By using this site, you agree to our Terms of Service.